GMDA
- Gamida Cell Ltd.
()
Overview
Company Summary
Gamida Cell Ltd. is a biotechnology company that operates in the field of cell therapy. The company focuses on developing advanced cell therapies for the treatment of various medical conditions, particularly blood cancers and serious hematologic diseases.
Gamida Cell aims to address the limitations of traditional cell therapies by utilizing its proprietary technology, known as NAM-based cell expansion. This technology allows for the expansion of stem and progenitor cells derived from different sources, such as umbilical cord blood, bone marrow, and peripheral blood. By expanding these cells outside the body, Gamida Cell can increase the number of therapeutic cells available for transplantation, enhancing the potential efficacy of the treatment.
One of the key products in Gamida Cell's pipeline is called NiCord, a nicotinamide (NAM) expanded cord blood cell therapy. NiCord is being developed as an alternative to traditional bone marrow transplantation for patients in need of a hematopoietic stem cell transplant (HSCT). HSCT is commonly used for the treatment of blood cancers, such as leukemia and lymphoma, as well as other hematologic disorders.
Gamida Cell is also exploring the application of its technology in other areas, including solid tumors and autoimmune diseases. The company is focused on advancing its pipeline through clinical trials, seeking regulatory approvals, and ultimately bringing its cell therapies to market.
In summary, Gamida Cell Ltd. is a biotechnology company that specializes in the development of cell therapy treatments, with a particular focus on blood cancers and hematologic diseases. Through its proprietary NAM-based cell expansion technology, Gamida Cell aims to improve the efficacy and availability of cell therapies, potentially offering better treatment options for patients in need.